1. constipations
2. pharmacological
2.1. Placebo effect ?
2.2. Side Effects
2.2.1. sleep disorders
2.2.2. drug interactions
2.2.3. L-Dopa
2.2.3.1. dyskinesia
2.2.3.2. on/off effects
2.2.3.3. nausea
2.2.4. psychosis
2.2.5. Abnormal sex behaviour
2.3. Oral treatment
2.3.1. Drugs
2.3.1.1. L-Dopa
2.3.1.1.1. loss of efficiacy after some years
2.3.1.2. Carboxylase Inhibitors
2.3.1.2.1. Benserazide
2.3.1.2.2. Carbidopa
2.3.1.3. MAO-B Inhibitors
2.3.1.4. Anticholinergic
2.3.1.5. Amantadine
2.3.1.6. Dopamine Agonists
2.3.1.7. Combination of several drugs
2.3.1.8. COMT Inhibitors
2.4. Advanced (pump) treatment
2.4.1. Duodopa pump
2.4.2. Apomorphine pen/pump
3. Treatment of PD (incurable so far)
3.1. experimental
3.1.1. Stem Cell Therapy
3.1.2. TMS
3.1.3. gene therapy
3.2. social
3.2.1. Cyper-Support (Internet support)
3.2.2. Social care and Support
3.2.3. Doctor Patient Relationship
3.2.4. Family Support
3.3. Community
3.3.1. Awareness
3.3.2. Health Care Providers
3.3.2.1. specialist PD Nurses
3.3.3. Charity
3.3.4. Parkinsons' Patient Organisation
3.3.5. Home Care
3.4. other
3.4.1. Psychiatric/psychological therapy
3.4.2. physiotherapy
3.4.3. speech/language therapy
3.4.4. sport/physical exercise
3.4.5. diat
3.4.5.1. Role of natural fruits/ black berries
3.4.6. Faith/Religiousity
3.5. education
4. Babiński's sign absent
5. How to speed up transition from dishes and animal models to promising Phase I?
6. Funding
6.1. Non profits
6.1.1. Michael J Fox Foundation
6.1.2. Parkinson UK
6.2. Public
6.2.1. UK NHS
6.2.2. EU (Framework Programmes)
6.2.3. US NIH
6.3. Big Pharmas
6.4. Patients
6.4.1. Crowdfunding
6.5. National/International funding?
7. non-motor symptoms
7.1. sexual disfunctions
7.2. decreased libido
7.3. sleeping disorders
7.4. unmodulated voice
7.5. difficulty swallowing
8. motor symptoms
8.1. akinesy
8.2. rigidity
8.3. hipertony
8.4. loss of balance
8.5. choreic movements
8.6. diskinesia
8.7. movement disorders
8.7.1. fine movement disorders
8.7.2. small steps
9. tremor
10. surgical
10.1. Deep Brain Stimulation
10.2. Surgical Ablation
11. Epidemiology
11.1. 2:3 M:F
11.2. 55-75 years
11.2.1. New node
11.3. #2nd neurodegenerative disorder
11.4. early onset 21-30(genetic, toxins)
11.5. indications that 20% debut before age 40
12. Etiology
12.1. Genetics
12.1.1. Dominant Gene
12.1.2. Recessive Gene
12.1.3. Genetic mutations
12.1.3.1. SNCA
12.1.3.2. PARKIN
12.1.3.3. PINK
12.1.3.4. DY-1
12.1.3.5. LRRK2
12.2. Infectious
12.3. Toxic
12.3.1. Alcholic
12.3.2. Pesticides
12.3.3. MPTP
12.3.4. Copper
12.4. Unknown
12.5. Mitochondrial Dysfunction
12.6. Protein Agreggation
12.6.1. Amyloid
12.6.2. Lewy-Bodies
12.7. Drug Induced
12.7.1. Metoclopramide
12.7.2. Rotenone
12.8. Imunological
13. Symptoms
13.1. psychology
13.1.1. anxiety
13.1.2. depression
13.1.3. dementia
13.1.4. psychosis
13.1.5. hallucinations
13.1.6. apathy
13.1.7. changes in behaviour
13.1.7.1. gambling
13.1.7.2. isolation
13.2. disease-related?
13.3. drug-induced?
14. Physiopathology
14.1. DOPAMINE DOWN
14.1.1. New node
14.2. ACETYLCHOLINE UP
14.3. BASAL GANGLIA
14.4. SUBSTANTIA NIGRA
14.5. Dopamine Pathways
14.6. Links with other diseases
14.6.1. Neurodegenerative disease
14.6.2. Parkinson-Altzheimers connections
14.6.3. Parkinson plus diseases
14.6.3.1. Lewy-Body Dementia
14.6.3.2. Supranuclear Palsy
14.6.3.3. Multiple System Atrophy
14.6.4. Secondary Parkinsonism
14.6.4.1. Wilson's disease
14.6.4.2. Traumatic
14.6.4.3. Vascular
14.6.4.4. Medical induced
14.6.4.4.1. anti-psychotics
15. Social Aspects
15.1. Social Isolation
15.2. Public perception of disease
15.3. Social Burden
15.4. Patient Organisation
15.4.1. Parkinson UK
15.5. Economic Burden
15.6. Stigma
15.7. Effect of family
15.8. Famous Parkinson patients
15.8.1. Mohamed Ali
15.8.2. Pope Jean Paul II
15.8.3. Michael J.Fox
15.8.4. Hitler
15.8.5. Andy Grove
16. diagnosis
16.1. clinical examination
16.1.1. tendon reflexes
16.2. paraclinical examination
16.2.1. EEG
16.2.2. dopamine level measuring
16.2.3. ERPs
16.2.4. genetical testsn
16.2.5. DAT Scans
16.2.6. PET/SPECT scan